Search research articles
Contact Us
Filters
Showing results (11-20 of 42) with videos related to
Page
of 5
Sort By:
Eye & Contact Lens
|
July 31, 2019
Efficacy and Safety of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, for the Treatment of Keratoconjunctivitis Sicca: Pooled Analysis of a Phase 2b/3 and Phase 3 Study
John Sheppard, Shane Kannarr, Jodi Luchs, et al.
American Journal of Ophthalmology
|
December 10, 2002
Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure
Henry D Jampel, Jason Bacharach, Wang-Pui Sheu, et al.
Clinical Ophthalmology (Auckland, N.Z.)
|
September 7, 2023
Preservative-Free versus Benzalkonium Chloride-Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial
Jason Bacharach, Iqbal Ike K Ahmed, Elizabeth D Sharpe, et al.
Clinical Ophthalmology (Auckland, N.Z.)
|
December 20, 2022
Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial
Barry A Schechter, Maitee Urbieta, Jason Bacharach, et al.
Translational Vision Science & Technology
|
March 15, 2024
Validation of a Wearable Virtual Reality Perimeter for Glaucoma Staging, The NOVA Trial: Novel Virtual Reality Field Assessment
Chris Bradley, Iqbal Ike K Ahmed, Thomas W Samuelson, et al.
Clinical Ophthalmology (Auckland, N.Z.)
|
April 20, 2026
Efficacy and Safety of Preservative-Free Bimatoprost 0.01% Gel in Patients with Open-Angle Glaucoma and Ocular Hypertension: Results from Two Phase III Randomized Trials
Jason Bacharach, Eydie Miller-Ellis, Paul Harasymowycz, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
August 16, 2024
Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study
Jason Bacharach, Eugene B McLaurin, Steven Silverstein, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
November 15, 2022
Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies
Robert N Weinreb, Jason Bacharach, Jacob W Brubaker, et al.
Ophthalmology Science
|
June 12, 2025
Double-Masked, Dose-Response, Vehicle-Controlled Study of VVN461 Ophthalmic Solution in Postoperative Ocular Inflammation
James H Peace, Kevin Y Jong, Jason Bacharach, et al.
Advances in Therapy
|
March 14, 2020
Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2
Sanjay Asrani, Jason Bacharach, Edward Holland, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 42) with videos related to
Sort By:
Page
of 5
Eye & Contact Lens
|
July 31, 2019
Efficacy and Safety of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, for the Treatment of Keratoconjunctivitis Sicca: Pooled Analysis of a Phase 2b/3 and Phase 3 Study
John Sheppard, Shane Kannarr, Jodi Luchs, et al.
American Journal of Ophthalmology
|
December 10, 2002
Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure
Henry D Jampel, Jason Bacharach, Wang-Pui Sheu, et al.
Clinical Ophthalmology (Auckland, N.Z.)
|
September 7, 2023
Preservative-Free versus Benzalkonium Chloride-Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial
Jason Bacharach, Iqbal Ike K Ahmed, Elizabeth D Sharpe, et al.
Clinical Ophthalmology (Auckland, N.Z.)
|
December 20, 2022
Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial
Barry A Schechter, Maitee Urbieta, Jason Bacharach, et al.
Translational Vision Science & Technology
|
March 15, 2024
Validation of a Wearable Virtual Reality Perimeter for Glaucoma Staging, The NOVA Trial: Novel Virtual Reality Field Assessment
Chris Bradley, Iqbal Ike K Ahmed, Thomas W Samuelson, et al.
Clinical Ophthalmology (Auckland, N.Z.)
|
April 20, 2026
Efficacy and Safety of Preservative-Free Bimatoprost 0.01% Gel in Patients with Open-Angle Glaucoma and Ocular Hypertension: Results from Two Phase III Randomized Trials
Jason Bacharach, Eydie Miller-Ellis, Paul Harasymowycz, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
August 16, 2024
Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study
Jason Bacharach, Eugene B McLaurin, Steven Silverstein, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
November 15, 2022
Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies
Robert N Weinreb, Jason Bacharach, Jacob W Brubaker, et al.
Ophthalmology Science
|
June 12, 2025
Double-Masked, Dose-Response, Vehicle-Controlled Study of VVN461 Ophthalmic Solution in Postoperative Ocular Inflammation
James H Peace, Kevin Y Jong, Jason Bacharach, et al.
Advances in Therapy
|
March 14, 2020
Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2
Sanjay Asrani, Jason Bacharach, Edward Holland, et al.
Page
of 5